Gary R. Matzke

Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Gary R. Matzke, George R. Aronoff, Arthur J. Atkinson et al. · Kidney International · 2011 · 455 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Pharmacokinetics of vancomycin in patients with various degrees of renal function

Gary R. Matzke, R. McGory, C E Halstenson et al. · Antimicrobial Agents and Chemotherapy · 1984 · 362 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17

Liver disease selectively modulates cytochrome P450–mediated metabolism

Reginald F. Frye, N ZGHEIB, Gary R. Matzke et al. · Clinical Pharmacology & Therapeutics · 2006 · 246 citations

Medicine, Pharmacology, Biochemical Pharmacology +16

Validation of the five-drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug-metabolizing enzymes*

Reginald F. Frye, Gary R. Matzke, Adedayo Adedoyin et al. · Clinical Pharmacology & Therapeutics · 1997 · 241 citations

Medicine, Pharmacokinetics, Pharmacology +14

Analgesics and the kidney: Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc Committe of the National Kidney Foundation

William L. Henrich, Lawrence E. Agodoa, Brendan J. Barrett et al. · American Journal of Kidney Diseases · 1996 · 177 citations

Medicine, Nephrology, Pharmacology +16